ストックスクリーナーアプリを入手
873.68
0.06%
0.56
アフターアワーズ：
872.29
-1.39
-0.16%
前日終値:
$873.12
開ける：
$880.62
24時間の取引高:
3.76M
Relative Volume:
1.06
時価総額：
$830.35B
収益：
$45.04B
当期純損益:
$10.59B
株価収益率:
74.61
EPS:
11.71
ネットキャッシュフロー:
$414.30M
1週間 パフォーマンス:
+3.48%
1か月 パフォーマンス:
+17.69%
6か月 パフォーマンス:
-8.22%
1年 パフォーマンス:
+17.13%
1日の値動き範囲:
$873.43
$894.40
1週間の範囲:
$851.36
$894.40
52週間の値動き範囲:
$711.40
$972.53
Lilly Eli Co Stock (LLY) Company Profile
LLY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
873.68 | 830.35B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
88.08 | 390.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
ABBV
Abbvie Inc
|
202.08 | 356.74B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.30 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
89.50 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-09-13 | 再開されました | Citigroup | Buy |
| 2024-08-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-02-21 | ダウングレード | DZ Bank | Buy → Hold |
| 2024-02-16 | 繰り返されました | Morgan Stanley | Overweight |
| 2023-12-21 | ダウングレード | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-20 | 再開されました | UBS | Buy |
| 2023-08-09 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-26 | 繰り返されました | Citigroup | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-24 | 繰り返されました | BofA Securities | Buy |
| 2023-05-24 | 繰り返されました | UBS | Buy |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-15 | ダウングレード | Societe Generale | Hold → Sell |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-09-22 | アップグレード | UBS | Neutral → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-03-10 | 開始されました | Daiwa Securities | Outperform |
| 2022-01-21 | アップグレード | DZ Bank | Hold → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-16 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-16 | 繰り返されました | BofA Securities | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-11 | アップグレード | Berenberg | Hold → Buy |
| 2021-09-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-05 | アップグレード | DZ Bank | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-06-24 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2021-01-19 | アップグレード | Mizuho | Neutral → Buy |
| 2020-12-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-09-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-04-21 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2019-12-18 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-04-24 | アップグレード | Edward Jones | Hold → Buy |
| 2019-04-11 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-03-12 | 開始されました | JP Morgan | Overweight |
| 2019-01-23 | 開始されました | UBS | Buy |
| 2018-11-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-10-31 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-10-01 | 繰り返されました | SunTrust | Buy |
| 2018-09-26 | 再開されました | JP Morgan | Overweight |
すべてを表示
Lilly Eli Co (LLY) 最新ニュース
Eli Lilly Has Exclusivity Over Weight Loss Drug, FDA Says - Law360
Lilly Endowment sells $12.9 million in Eli Lilly stock - Investing.com
Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight - GlobeNewswire Inc.
Is Eli Lilly and Company (LLY) the Best Non-Tech Stock to Buy Now for Long Term? - Insider Monkey
Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile - Reuters
Major Shareholder Makes a Big Move with Eli Lilly & Co Stock! - TipRanks
Lilly Endowment Inc sells $8.77 million in Eli Lilly shares By Investing.com - Investing.com UK
ELI LILLY AND COMPANY (LLY) - MSN
Eli Lilly's Options Frenzy: What You Need to Know - Benzinga
The Alzheimer's Drug Discovery Foundation Announces Daniel M. Skovronsky, MD, PhD, of Eli Lilly & Company, as Recipient of Prestigious 2025 Melvin R. Goodes Prize - citybiz
Eli Lilly and Company (LLY): Among the Best Long-Term Stocks to Buy According to Ken Fisher - Insider Monkey
Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile By Reuters - Investing.com
Eli Lilly’s (NYSE:LLY) Future Takes Aim at Big Problems in Plain Sight - TipRanks
Eli Lilly wants to use its weight loss drug windfall to fight Alzheimer's and hearing loss - Yahoo Finance
Eli Lilly obesity drug trial participants losing ‘too much weight,’ STAT reports - TipRanks
Eli Lilly aims to invest in 'big problems hiding in plain sight' using obesity windfall - CNBC
From pills to new uses, here's what Eli Lilly’s top scientist sees as the future of weight loss drugs - CNBC
Eli Lilly Files For Mixed Shelf Size Not DisclosedSEC Filing -February 19, 2025 at 05:46 pm EST - Marketscreener.com
Eli Lilly & Co. (LLY) Files Mixed Shelf - StreetInsider.com
Lilly, Novo Fight Weight Loss Drug Compounders Over Shortage - Bloomberg Law
ELI LILLY & Co SEC 10-K Report - TradingView
SEC Form 10-K filed by Eli Lilly and Company - Quantisnow
Fat, not muscle: drugmakers in race for next weight-loss breakthrough -February 19, 2025 at 10:06 am EST - Marketscreener.com
Digging Into What Hershey and Eli Lilly Told Investors - The Motley Fool
Merck, Lilly launch manufacturing R&D consortium to help ‘bolster’ U.S. production - PharmaVoice
Fat, not muscle: drugmakers in race for next weight-loss breakthrough -February 19, 2025 at 06:08 am EST - Marketscreener.com
Eli Lilly and Company (LLY): A Bull Case Theory - MSN
Lebanon planning board OKs design for Lilly Medicine Foundry at LEAP District - Indianapolis Business Journal
APAC deals abound: Lilly taps Advancell, Olix; Genome draws Ellipses - BioWorld Online
Lilly to participate in TD Cowen's 45th Annual Health Care Conference - Investors | Eli Lilly and Company
The Zacks Analyst Blog Highlights Apple, Eli Lilly, Shopify and ImmuCell - Yahoo Finance
Eli Lilly and Company (NYSE:LLY) Trading Down 3.1%Here's What Happened - MarketBeat
Chronic Lower Back Pain Market Expected to rise, 2034 | Eli Lilly - openPR
Eli Lilly & Co: Promising Growth Driven by Innovative Pipeline and Market-Leading Weight-Loss Treatments - TipRanks
TigerOak Management L.L.C. Takes $522,000 Position in Eli Lilly and Company (NYSE:LLY) - MarketBeat
Why Eli Lilly and Company (LLY) Is the Best Drug Stock to Buy Now - Insider Monkey
Eli Lilly Reports Record Q4 2024 Revenue of $13.53B, Fueled by Mounjaro, Zepbound, and Oncology Growth - BSA bureau
Lebanon planning board to review designs for Lilly’s $4.5B foundry at LEAP District - Inside INdiana Business
Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake - The Motley Fool
1,149 Shares in Eli Lilly and Company (NYSE:LLY) Acquired by CFC Planning Co LLC - MarketBeat
Eli Lilly Full-Year Earnings Meet Expectations Amid GLP-1 Inventory Challenges – market - HPBL
Major Shareholder Makes a Significant Move with Eli Lilly & Co Stock! - TipRanks
Top Stock Reports for Apple, Eli Lilly & Shopify - Yahoo Finance
Lilly Endowment sells $31.18 million in Eli Lilly stock - Investing.com
Innovating beyond boundaries: Sarah O’Keeffe’s career in making medicine - Irish Examiner
1,080 Shares in Eli Lilly and Company (NYSE:LLY) Bought by Kentucky Trust Co - MarketBeat
Eli Lilly leads M&A bond charge in US IG market - GlobalCapital
Is Eli Lilly and Company (LLY) the Best Large Cap Dividend Growth Stock to Buy Now? - Insider Monkey
Single Point Partners LLC Buys New Position in Eli Lilly and Company (NYSE:LLY) - MarketBeat
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy? - MSN
Eli Lilly issues $6 billion in new debt securities - MSN
Lilly Eli Co (LLY) 財務データ
収益
当期純利益
現金流量
EPS
5.18%
大文字化:
|
ボリューム (24 時間):